| RESERVED AREA | LANGUAGE

Lung Cancer Study Group

(Português) home-2022

N E W S

New Journal of the Lung Cancer Study Group

New Journal of the Lung Cancer Study Group

The Journal of the Lung Cancer Study Group, Vol. XIX, nº2 of 2021, is now available for consultation and free download here! Access https://www.gecp.pt/revistas/ to consult this edition and other issues from previous years of Revista do GECP And if…

BANNER-10CONGRESSOPULMAO

10th GECP Congress

The 10th GECP Congress, which opens the Portuguese Lung Cancer Congress, will take place on the 20th, 21st and 22nd of October, in Troia, in an entirely face-to-face format. In this event, under the theme “Lugar ao Novo”, “we will…

Don’t Play With Your Life: Lung Cancer Is Not a Game

Don’t Play With Your Life: Lung Cancer Is Not a Game

“Don’t gamble with your life” is the alert from the Lung Cancer Study Group (GECP) on the occasion of the International Gamer Day, celebrated annually on August 29, with the aim of putting the topic of lung cancer on the…

MEN-MADE-CANCER-2022

Men Made Cancer

Men Made Cancer: “Lung cancer is the biggest killer, but its main risk factors are modifiable” “Men Made Cancer” is the motto of the new campaign by the Lung Cancer Study Group (GECP) for World Lung Cancer Day, which is…

Tecentriq (atezolizumab) gets Infarmed approval for new indications

Tecentriq (atezolizumab) gets Infarmed approval for new indications

The drug Tecentriq (atezolizumab) obtained authorization from the National Authority for Medicines and Health Products (Infarmed) to be used in hospitals in new indications for the treatment of lung cancer. According to the grant recently published on the Infarmed website,…

artigo_escolhido_gecp_14julho2022

Chosen Article

Dr. Fernanda EstevinhoOncologist at Hospital Pedro Hispano – ULS MatosinhosSelected Article: “Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data” O artigo selecionado…

P U B L I C A T I O N S

HOT TOPICS

“ASSOCIAÇÕES DE IMUNOTERAPIA EM DOENTES CPNPC EM ESTADIO IV”

New Therapeutic Approaches

2 1 Y E A R S O F H I S T O R Y I N P E R S P E C T I V E

2000

FOUNDED IN

204

MEMBERS

10

STUDIES

41

CENTROS ASSOCIATES

S U P P O R T

©2022 Copyright GECP